Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChesnara Regulatory News (CSN)

Share Price Information for Chesnara (CSN)

Share Price is delayed by 15 minutes
Get Live Data
317.50    0.50 (0.16%)
Bid:
315.50
Ask:
317.00
Spread: 1.50 (0.475%)
Market Cap: £732.37m
CSN Live PriceLast checked at - London Stock Exchange

Intraday Chesnara Share Chart

Total Voting Rights

31 Jul 2023 07:00

RNS Number : 5826H
Chesnara PLC
31 July 2023
 

 

 

LEI Number: 213800VFRMBRTSZ3SJ06

 

 

31st July 2023

 

CHESNARA plc

("Chesnara" or "the Company")

 

TOTAL VOTING RIGHTS

 

In conformity with 5.6.1 of the Disclosure Guidance and Transparency Rules, the Company notifies the market of the following: -

 

Chesnara's (CSN.L) issued share capital as at the date of this announcement comprised of 150,590,912 ordinary shares of 5p each with no shares held in Treasury. Each share carries one voting right and therefore the total number of voting rights is 150,590,912.

 

This figure of 150,590,912 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information, please contact:

 

Investor Enquiries

Sam Perowne

Head of Strategic Development & Investor Relations

Chesnara plc

E - sam.perowne@chesnara.co.uk

 

Media Enquiries

Roddy Watt

Director, Capital Markets

FWD

T - 020 7280 0651 / 07714 770 493 

E - roddy.watt@fwdconsulting.co.uk

 

Notes to Editors

Chesnara (CSN.L) is a European life and pensions consolidator listed on the London Stock Exchange. It administers approximately one million policies and operates as Countrywide Assured and CASLP in the UK, as The Waard Group and Scildon in the Netherlands, and as Movestic in Sweden.

 

Following a three-pillar strategy, Chesnara's primary responsibility is the efficient administration of its customers' life and savings policies, ensuring good customer outcomes and providing a secure and compliant environment to protect policyholder interests. It also adds value by writing profitable new business in Sweden and the Netherlands and by undertaking value-adding acquisitions of either companies or portfolios.

 

Consistent delivery of the Company strategy has enabled Chesnara to increase its dividend for 18 years in succession.

 

Further details are available on the Company's website (www.chesnara.co.uk).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRUWORROKUBUAR
Date   Source Headline
8th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSDirectorate Change
29th Nov 202312:00 pmRNSHolding(s) in Company
21st Nov 202312:55 pmEQSHardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management
17th Nov 20233:30 pmRNSDirector/PDMR Shareholding
15th Nov 202312:00 pmRNSDirector/PDMR Shareholding
15th Nov 20237:00 amRNSUpdate on AGM Voting
25th Oct 20237:00 amRNSBlock listing Interim Review
25th Oct 20237:00 amRNSHolding(s) in Company
23rd Oct 20237:00 amRNSDirector/PDMR Shareholding
20th Oct 202310:30 amEQSHardman & Co Analyst Interview on Chesnara plc (CSN): A robust approach to cash generation
4th Oct 20233:30 pmEQSHardman & Co Research: Chesnara plc (CSN) - Good first half aided by markets and acquisitions
21st Sep 20237:00 amRNSHalf-year Report
1st Sep 20237:00 amRNSNotice of Half Year Results
31st Jul 20237:00 amRNSTotal Voting Rights
17th Jul 20237:00 amRNSAppointment of Joint Corporate Broker
11th Jul 202311:45 amRNSDirector/PDMR Shareholding
7th Jul 20237:00 amRNSDirector/PDMR Shareholding
29th Jun 20239:15 amRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmEQSCORRECTION Hardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management
6th Jun 202310:30 amEQSHardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management
2nd Jun 20232:10 pmRNSDirector/PDMR Shareholding
31st May 20237:00 amRNSTotal Voting Rights
23rd May 20231:05 pmEQSHardman & Co Research on Chesnara plc (CSN): Nice little acquisition
22nd May 20237:00 amRNSNew strategic partnership for Chesnara Plc
19th May 20237:00 amRNSDirector/PDMR Shareholding
16th May 20232:24 pmRNSResult of AGM
16th May 20237:00 amRNSAcquisition
4th May 20232:30 pmEQSHardman & Co Q&A on Chesnara plc (CSN): Strong cash generation through tough markets
28th Apr 20237:00 amRNSTotal Voting Rights
25th Apr 20237:00 amRNSBlock listing Interim Review
21st Apr 202312:27 pmRNSHolding(s) in Company
19th Apr 20237:00 amRNSNotice of AGM
11th Apr 20238:05 amEQSHardman & Co Research on Chesnara plc (CSN): Great cash flow in tough markets
31st Mar 20237:00 amRNSTotal Voting Rights
30th Mar 20237:00 amRNSFinal Results
1st Mar 20237:00 amRNSNotice of Results
28th Feb 20237:00 amRNSTotal Voting Rights
17th Feb 20237:00 amRNSHolding(s) in Company
31st Jan 20237:00 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSTotal Voting Rights
19th Dec 20227:00 amRNSHolding(s) in Company
16th Dec 20227:00 amRNSAcquisition
30th Nov 20227:00 amRNSTotal Voting Rights
15th Nov 20227:00 amRNSHolding(s) in Company
14th Nov 20227:00 amRNSDirector/PDMR Shareholding
11th Nov 20227:00 amRNSDirector/PDMR Shareholding
1st Nov 202212:15 pmRNSDirector/PDMR Shareholding
31st Oct 20227:00 amRNSTotal Voting Rights
27th Oct 20222:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.